Newer antifungal agents

Current Opinion in Pediatrics

Volumn 25, Issue 1, 2013, Pages 110-115

  Larru, Beatriz ^a   Zaoutis, Theoklis E ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

amphotericin; antifungal; azole; children; echinocandin

Indexed keywords

ALBACONAZOLE; AMINOCANDIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; CANDIDEMIA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CROSS RESISTANCE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UNDERDOSE; FUSARIOSIS; HISTOPLASMOSIS; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MENINGOENCEPHALITIS; NEPHROTOXICITY; NEWBORN INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PSEUDALLESCHERIASIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CHILD; ECHINOCANDINS; HUMANS; MYCOSES;

EID: 84873097432     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32835c1fc2     Document Type: Review

References (53)

1. Tragiannidis A, Dokos C, Lehrnbecher T, Groll AH. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: Review of the literature and options for clinical practice. Drugs 2012; 72:685-704
2. Pappas PG. Opportunistic fungi: A view to the future. Am J Med Sci 2010; 340:253-257
3. Cecinati V, Guastadisegni C, Russo FG, Brescia LP. Antifungal therapy in children: An update. Eur J Pediatr 2012. [Epub ahead of print
4. Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010; 54:4143-4149
5. Maertens JA, Madero L, Reilly AF, et al A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415-420
6. Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J 2009; 28:1061-1063
7. Arrieta AC, Shea K, Dhar V, et al. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: A prospective, randomized, open-label, placebo-controlled pilot study. Clin Ther 2010; 32:265-271
8. Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: Deoxycholate or lipid formulation as first-line therapy - is there a 'right' choicëCurr Opin Infect Dis 2011; 24:163-171
9. Hope WW, Castagnola E, Groll AH, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012. doi:10.1111/1469-0691.12040. [Epub ahead of print
10. Clerihew L, McGuire W. Antifungal therapy for newborn infants with invasive fungal infection. Cochrane Database Syst Rev 2012:CD003953
11. Ascher SB, Smith PB, Watt K, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J 2012; 31:439-443
12. Mann PA, McNicholas PM, Chau AS, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009; 53:5026-5034
13. Dotis J, Prasad PA, Zaoutis T, Roilides E. Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children. Pediatr Infect Dis J 2012; 31:557-560
14. Blyth CC. HKPPOTBM: Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010:CD006343
15. Kaufman DA, Cuff AL, Wamstad JB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011; 158:759-765
16. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010; 16:1343-1353
17. Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155:318-327
18. Hicheri Y, Cook G, Cordonnier C. Antifungal prophylaxis in haematology patients: The role of voriconazole. Clin Microbiol Infect 2012; 18:1-15
19. Mandhaniya S, Swaroop C, Thulkar S, et al. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: A prospective, randomized, clinical study. J Pediatr Hematol Oncol 2011; 33:e333-e341
20. Molina JR, Serrano J, Sanchez-Garcia J, et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. Bone Marrow Transplant 2012; 47:562-567
21. Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50:27-36
22. Soler-Palacin P, Frick MA, Martin-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study. J Antimicrob Chemother 2012; 67:700-706
23. Doby EH, Benjamin DK Jr, Blaschke AJ, et al. Therapeutic monitoring of Voriconazole in children less than three years of age. Pediatr Infect Dis J 2012; 31:632-635
24. Pieper S, Kolve H, Gumbinger HG, et al. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother 2012; 67:2717-2724
25. Michael C, Bierbach U, Frenzel K, et al. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother 2010; 54:3225-3232
26. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54:4116-4123
27. Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-To-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother 2011; 55:5770-5779
28. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 2012; 56:3032-3042
29. Michael C, Bierbach U, Frenzel K, et al. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults. Ther Drug Monit 2010; 32:194-199
30. Ashbee HR, Gilleece MH. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplant 2012; 47:881-894
31. Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections associated with standard long-Term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17:507-515
32. Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: A multicentre survey. Eur J Clin Microbiol Infect Dis 2010; 29:1043-1045
33. Katragkou A, Tsikopoulou F, Roilides E, Zaoutis TE. Posaconazole: When and how? The clinician's view. Mycoses 2011; 55:110-122
34. Welzen MEB, Brüggemann RJM, van den Berg JM, et al A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease. Pediatr Infect Dis J 2011; 30:794-797
35. Krishna G, Vickery D, Ma L, et al. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin. J Clin Pharmacol 2010; 51:84-92
36. Tü relO ?. Newer antifungal agents. ExpertRevAnti Infect Ther 2011; 9:325-338
37. Chen SCA, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections. Drugs 2011; 71:11-41
38. Caudle KE, Inger AG, Butler DR, Rogers PD. Echinocandin use in the neonatal intensive care unit. Ann Pharmacother 2012; 46:108-116
39. Naik S, Lundberg J, Kumar R, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand J Infect Dis 2011; 43:504-514
40. Zaoutis TE, Jafri HS, Huang LM, et al A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123:877-884
41. Wahab Mohamed WA, Ismail M A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. J Trop Pediatr 2012; 58:25-30
42. VandenBussche HL, Van Loo DA A clinical review of echinocandins in pediatric patients. Ann Pharmacother 2010; 44:166-177
43. Okamoto T, Koh K, Takita J, et al. Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia. Pediatr Int 2010; 52:137-141
44. Lehrnbecher T, Groll AH. Micafungin A brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer 2010; 55:229-232
45. Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011; 30:e97-e102
46. Undre NA, Stevenson P, Freire A, Arrieta A. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J 2012; 31:630-632
47. Ascher S, Smith PB, Benjamin DK Jr. Safety of micafungin in infants: Insights into optimal dosing. Expert Opin Drug Saf 2011; 10:281-286
48. Yanni SB, Smith PB, Benjamin DK Jr, et al. Higher clearance of micafungin in neonates compared with adults: Role of age-Dependent micafungin serum binding. Biopharm Drug Dispos 2011; 32:222-232
49. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54:2633-2637
50. Hoffman JA, Walsh TJ. Echinocandins in children. Pediatr Infect Dis J 2011; 30:508-509
51. Cohen-Wolkowiez M, Benjamin DK, Piper L, et al. Safety and pharmacokinetics of multiple-Dose anidulafungin in infants and neonates. Clin Pharmacol Ther 2011; 89:702-707
52. Warn PA, Livermore J, Howard S, et al. Anidulafungin for neonatal hematogenous candida meningoencephalitis: Identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother 2012; 56:708-714
53. Warn PA, Sharp A, Morrissey G, Denning DW. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. Int J Antimicrob Agents 2010; 35:146-151